Share chart Karuna Therapeutics, Inc.
Extended chart
Simple chart
About
Karuna Therapeutics, Inc., биофармацевтическая компания, работающая на клинической стадии, в первую очередь занимается разработкой новых методов лечения, направленных на устранение инвалидизирующих психоневрологических расстройств и боли.
More detailsP/E | 0.16 |
---|---|
P/BV | 2.16 |
EV/EBITDA | -14.8 |
EBITDA | -0.0429 |
Цена ао | 329.83 |
Сайт | http://www.karunatx.com |
Число акций ао | 0.03696 млрд |
P/S | 103.24 |
Выручка | 0.037 |
Див.доход ао | 0 |
ISIN | US48576A1007 |
Change price per day: | 0% (329.83) |
---|---|
Change price per week: | 0% (329.83) |
Change price per month: | 0% (329.83) |
Change price per 3 month: | 0% (329.83) |
Change price per half year: | 0% (329.83) |
Change price per year: | +77.82% (185.49) |
Change price per 3 year: | +169.8% (122.25) |
Change price per year to date: | +4.21% (316.51) |
All parameters ⇨
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Transaction date | Date of disclosure | Insider | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
---|---|---|---|---|---|---|---|---|---|
23.02.2024 | 26.02.2024 | PAUL STEVEN M Director |
Purchase | 19.03 | 599 788 | 31518 | 0 | 0.11 | link |
04.10.2022 | 04.10.2022 | Ignelzi Troy A. Chief Financial Officer |
Sale | 233.2 | 93 280 | 400 | 0 | 0 | link |
03.10.2022 | 04.10.2022 | Ignelzi Troy A. Chief Financial Officer |
Sale | 231.18 | 947 838 | 4100 | 0 | -0.01 | link |
30.09.2022 | 04.10.2022 | Ignelzi Troy A. Chief Financial Officer |
Sale | 228.86 | 2 403 030 | 10500 | 0 | -0.04 | link |
21.04.2022 | 21.04.2022 | Ignelzi Troy A. Chief Financial Officer |
Sale | 134.46 | 5 378 | 40 | 0 | 0 | link |
21.04.2022 | 21.04.2022 | Ignelzi Troy A. Chief Financial Officer |
Purchase | 9.2 | 368 | 40 | 0 | 0 | link |
20.04.2022 | 21.04.2022 | Ignelzi Troy A. Chief Financial Officer |
Sale | 133.2 | 93 773 | 704 | 0 | 0 | link |
20.04.2022 | 21.04.2022 | Ignelzi Troy A. Chief Financial Officer |
Purchase | 9.2 | 6 477 | 704 | 0 | 0 | link |
19.04.2022 | 21.04.2022 | Ignelzi Troy A. Chief Financial Officer |
Sale | 130.81 | 457 835 | 3500 | 0 | -0.01 | link |
19.04.2022 | 21.04.2022 | Ignelzi Troy A. Chief Financial Officer |
Purchase | 9.2 | 32 200 | 3500 | 0 | 0.01 | link |
Institutions | Volume | Share, % |
---|---|---|
Capital International Investors | 4227102 | 11.08 |
Vanguard Group Inc | 3224786 | 8.45 |
FMR, LLC | 2865994 | 7.51 |
T. Rowe Price Investment Management, Inc. | 2709629 | 7.1 |
Blackrock Inc. | 2015374 | 5.28 |
Price (T.Rowe) Associates Inc | 1961587 | 5.14 |
Sofinnova Investments, Inc. | 1381149 | 3.62 |
Wellington Management Group, LLP | 1134046 | 2.97 |
Pentwater Capital Management LP | 1066200 | 2.79 |
General Atlantic, L.P. | 986710 | 2.59 |
ETF | Share, % | Profitability for 1 year, % | Dividends, % |
---|---|---|---|
iShares Neuroscience and Healthcare ETF | 3.24 | 0.03 | |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Dr. Steven M. Paul M.D. | President of Research and Development, Chief Scientific Officer & Director | 1.32M | 1951 (73 years) |
Dr. Andrew Craig Miller | Co-Founder & COO | 835.4k | 1982 (42 years) |
Dr. Stephen K. Brannan | Chief Medical Officer | 751.75k | 1956 (68 years) |
Dr. Alan Breier | Chair of Scientific Advisory Board & Chief Clinical Advisor | N/A | |
Mr. William Meury | President, CEO & Director | N/A | 1968 (56 years) |
Ms. Mia Kelley J.D. | Vice President of Legal Affairs | N/A | |
Mr. Jason Parker Brown | Chief Financial Officer | N/A | |
Mr. Jonathan Rosin | Chief Human Resources Officer | N/A | |
Ms. Alexis Smith | Vice President of Corporate Affairs & Investor Relations | N/A | |
Mr. Frank Truslow | Senior Vice President of Corporate Development | N/A | |
Address: United States, Boston, MA , 33 Arch Street - open in Google maps, open in Yandex maps
Website: http://www.karunatx.com
Website: http://www.karunatx.com